Immune Checkpoint Inhibitor-related Endocrinopathies.
作者信息
Lu Difei, Gao Ying
机构信息
Department of Endocrinology, Peking University First Hospital, Beijing 100034, China.
出版信息
J Transl Int Med. 2022 Apr 2;10(1):9-14. doi: 10.2478/jtim-2022-0009. eCollection 2022 Mar.
Abstract
摘要
相似文献
1
Immune Checkpoint Inhibitor-related Endocrinopathies.免疫检查点抑制剂相关内分泌病
J Transl Int Med. 2022 Apr 2;10(1):9-14. doi: 10.2478/jtim-2022-0009. eCollection 2022 Mar.
2
Organ-specific Adverse Events of Immune Checkpoint Inhibitor Therapy, with Special Reference to Endocrinopathies.免疫检查点抑制剂治疗的器官特异性不良事件，特别提及内分泌病
touchREV Endocrinol. 2021 Apr;17(1):21-32. doi: 10.17925/EE.2021.17.1.21. Epub 2021 Apr 28.
3
Endocrinopathies Associated With Immune Checkpoint Inhibitor Use.与免疫检查点抑制剂使用相关的内分泌疾病。
Endocr Pract. 2024 Jun;30(6):584-591. doi: 10.1016/j.eprac.2024.03.023. Epub 2024 Mar 28.
4
American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach.美国临床内分泌学会疾病临床综述：免疫检查点抑制剂相关内分泌疾病的评估和管理：一种基于实际病例的临床方法。
Endocr Pract. 2022 Jul;28(7):719-731. doi: 10.1016/j.eprac.2022.04.010. Epub 2022 Apr 25.
5
Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review.与免疫检查点抑制剂癌症治疗相关的内分泌病：综述
J Clin Med. 2020 Jun 29;9(7):2033. doi: 10.3390/jcm9072033.
6
Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies.免疫检查点抑制剂相关内分泌疾病的急症表现。
J Emerg Med. 2021 Aug;61(2):140-146. doi: 10.1016/j.jemermed.2021.02.020. Epub 2021 Mar 29.
7
Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.绘制免疫检查点抑制剂的内分泌毒性谱：使用世界卫生组织药物不良反应数据库VigiBase进行的不成比例分析。
Endocrine. 2020 Sep;69(3):670-681. doi: 10.1007/s12020-020-02355-9. Epub 2020 Jun 7.
8
Immune Checkpoint Inhibitors-Induced Endocrinopathies: Assessment, Management and Monitoring in a Comprehensive Cancer Centre.免疫检查点抑制剂引起的内分泌疾病：综合癌症中心的评估、管理和监测。
Endocrinol Diabetes Metab. 2024 Jul;7(4):e00505. doi: 10.1002/edm2.505.
9
Immune checkpoint inhibitors-related endocrinopathies exhibit increased severity in breast cancer patients: a real-world study.免疫检查点抑制剂相关内分泌疾病在乳腺癌患者中表现出更高的严重程度：一项真实世界研究。
Endocrine. 2024 Sep;85(3):1446-1455. doi: 10.1007/s12020-024-03859-4. Epub 2024 Jun 29.
10
Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer.癌症免疫检查点抑制剂治疗后免疫相关内分泌病的诊断标准及建议管理
Endocr Connect. 2023 Apr 17;12(5). doi: 10.1530/EC-22-0513. Print 2023 May 1.
引用本文的文献
1
Pembrolizumab-Induced Thyroid Storm in a Patient With Triple-Negative Breast Cancer.帕博利珠单抗诱发三阴性乳腺癌患者甲状腺危象
AACE Endocrinol Diabetes. 2025 May 2;12(2):107-111. doi: 10.1016/j.aed.2025.04.008. eCollection 2025 Jul-Aug.
2
Improving assessment of financial toxicity of cancer immunotherapy.改善癌症免疫疗法财务毒性的评估。
Support Care Cancer. 2025 Jul 31;33(8):735. doi: 10.1007/s00520-025-09796-w.
3
Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes.免疫检查点抑制剂相关甲状腺炎：机制与临床结局
J Endocrinol Invest. 2025 Sep;48(9):2001-2012. doi: 10.1007/s40618-025-02608-2. Epub 2025 May 12.
4
Tegaserod maleate exerts anti-tumor effects on prostate cancer via repressing sonic hedgehog signaling pathway.马来酸替加色罗通过抑制音猬因子信号通路对前列腺癌发挥抗肿瘤作用。
Mol Med. 2025 Jan 29;31(1):30. doi: 10.1186/s10020-025-01080-1.
5
Integrating machine learning, bioinformatics and experimental verification to identify a novel prognostic marker associated with tumor immune microenvironment in head and neck squamous carcinoma.整合机器学习、生物信息学和实验验证，以鉴定与头颈部鳞状细胞癌肿瘤免疫微环境相关的新型预后标志物。
Front Immunol. 2024 Dec 10;15:1501486. doi: 10.3389/fimmu.2024.1501486. eCollection 2024.
6
The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience.免疫检查点抑制剂诱导的内分泌病的负担及临床病程：八年经验
BMC Med. 2024 Dec 18;22(1):588. doi: 10.1186/s12916-024-03812-2.
7
Prognostic model based on centrosome-related genes constructed in head and neck squamous cell carcinoma.基于头颈部鳞状细胞癌中与中心体相关基因构建的预后模型。
J Cancer. 2024 Oct 21;15(20):6531-6544. doi: 10.7150/jca.102057. eCollection 2024.
8
Pembrolizumab-induced Thyroiditis, Hypophysitis and Adrenalitis: A Case of Triple Endocrine Dysfunction.帕博利珠单抗诱发的甲状腺炎、垂体炎和肾上腺炎：一例三重内分泌功能障碍病例
JCEM Case Rep. 2024 Nov 4;2(11):luae200. doi: 10.1210/jcemcr/luae200. eCollection 2024 Nov.
9
Induction of interleukin-6 by SPZ1-mediated Wnt5a signaling boosts progression of nasopharyngeal carcinoma cells.SPZ1介导的Wnt5a信号通路诱导白细胞介素-6促进鼻咽癌细胞进展。
J Cancer. 2024 Oct 7;15(18):6148-6159. doi: 10.7150/jca.99648. eCollection 2024.
10
Thyroid Storm and Type 1 Diabetes Mellitus Induced by Combined Ipilimumab and Nivolumab Immunotherapy: A Case Report.伊匹木单抗和纳武单抗联合免疫疗法诱发的甲状腺风暴和1型糖尿病：一例报告
Cureus. 2023 Oct 13;15(10):e46985. doi: 10.7759/cureus.46985. eCollection 2023 Oct.
本文引用的文献
1
Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.免疫检查点抑制剂相关新发甲状腺功能障碍：使用美国 FDA 不良事件报告系统进行的回顾性分析。
Oncologist. 2022 Mar 4;27(2):e126-e132. doi: 10.1093/oncolo/oyab043.
2
Differences between immunotherapy-induced and primary hypophysitis-a multicenter retrospective study.免疫治疗相关性和原发性垂体炎的差异：一项多中心回顾性研究。
Pituitary. 2022 Feb;25(1):152-158. doi: 10.1007/s11102-021-01182-z. Epub 2021 Sep 13.
3
FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.成纤维细胞生长因子受体和程序性死亡配体 1 在间变性和低分化甲状腺癌中的作用：临床前原理的评估。
Front Endocrinol (Lausanne). 2021 Aug 12;12:712107. doi: 10.3389/fendo.2021.712107. eCollection 2021.
4
The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients.免疫检查点抑制剂诱发的甲状腺炎对总生存的积极影响：考虑不朽时间偏倚的一项对6596例患者的回顾性队列研究
Ann Oncol. 2021 Aug;32(8):1050-1051. doi: 10.1016/j.annonc.2021.05.357. Epub 2021 May 19.
5
CD4 T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice.在甲状腺球蛋白免疫的小鼠中，CD4 T细胞对于抗PD-1抗体诱导的破坏性甲状腺炎的发展至关重要。
Sci Transl Med. 2021 May 12;13(593). doi: 10.1126/scitranslmed.abb7495.
6
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.2021 年美国甲状腺协会甲状腺间变性癌患者管理指南。
Thyroid. 2021 Mar;31(3):337-386. doi: 10.1089/thy.2020.0944.
7
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.免疫检查点抑制剂在肺大细胞神经内分泌肿瘤中的真实世界生存结果。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001999.
8
Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature.免疫检查点抑制剂引起的糖尿病：1 型糖尿病变异型还是新的临床实体？文献复习。
Rev Endocr Metab Disord. 2021 Jun;22(2):337-349. doi: 10.1007/s11154-020-09618-w. Epub 2021 Jan 6.
9
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review.免疫检查点抑制剂诱发的自身免疫性多内分泌腺综合征：系统综述。
Cancer Immunol Immunother. 2021 Jun;70(6):1527-1540. doi: 10.1007/s00262-020-02699-1. Epub 2020 Nov 16.
10
Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series.原发和伊匹单抗诱导的垂体炎：单中心病例系列。
Endocr Res. 2020 Nov;45(4):246-253. doi: 10.1080/07435800.2020.1817064. Epub 2020 Sep 5.
Zotero 插件